Mishra_2013_Neurosci_250C_309

We explored the attenuating effects of NP-9 on beta-amyloid (Abeta) aggregation and amyloid-induced toxicity. NP-9 is a recently reported monoamine oxidase B (MAO-B), and acetylcholinesterase (AChE) inhibitor. In the present study, we found that NP-9 inhibited AChE activity in a dose-dependent manner with a maximal inhibition dose of 8mg/kg, i.p. It inhibited Abeta aggregation, observed through thioflavin-T assay (IC50=60muM) and scanning electron microscopy (S.E.M.) (no fibril formation). NP-9 has shown marked protection against scopolamine and Abeta1-42-induced memory impairments. It also minimized neuronal loss and amyloid plaque deposition in the brains of Abeta1-42-induced mice model. Therefore, NP-9 could be a promising lead molecule for AD, with effects against MAO-B, AChE, Abeta aggregation, and Abeta1-42 induced toxicity.